Antibodies News and Research

RSS
Special type of stem cell can reduce the amount of HIV virus

Special type of stem cell can reduce the amount of HIV virus

COVID-19 prevalence in the U.S. has far exceeded the known number of cases

COVID-19 prevalence in the U.S. has far exceeded the known number of cases

New antibody conjugate delivers drugs to bone tumors and inhibits metastasis

New antibody conjugate delivers drugs to bone tumors and inhibits metastasis

Research suggests people living with HIV/AIDS may be less susceptible to SARS-CoV-2

Research suggests people living with HIV/AIDS may be less susceptible to SARS-CoV-2

NIH begins study to evaluate how pregnant, postpartum people react to COVID-19 vaccines

NIH begins study to evaluate how pregnant, postpartum people react to COVID-19 vaccines

Three CU researchers recognized for contributions to immunotherapy in childhood cancer

Three CU researchers recognized for contributions to immunotherapy in childhood cancer

Repeated vaccination could control infection with SARS-CoV-2 variants among infection-naïve individuals

Repeated vaccination could control infection with SARS-CoV-2 variants among infection-naïve individuals

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

A study on hospitalized COVID-19 patients who received plasma therapy

A study on hospitalized COVID-19 patients who received plasma therapy

Higher levels of antibodies from COVID-19 mRNA vaccine compared to natural SARS-CoV-2 infection

Higher levels of antibodies from COVID-19 mRNA vaccine compared to natural SARS-CoV-2 infection

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

Vaccinated individuals previously infected with SARS-CoV-2 show robust neutralization of the B.1.1.7 variant

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

Longitudinal study finds SARS-CoV-2 neutralizing antibodies decline a year after infection

Researchers review the origins of SARS-CoV-2 and present treatment methods

Researchers review the origins of SARS-CoV-2 and present treatment methods

New study enrolls young adults to evaluate SARS-CoV-2 infection

New study enrolls young adults to evaluate SARS-CoV-2 infection

More than 16 million Americans had undiagnosed SARS-CoV-2 infections during first wave

More than 16 million Americans had undiagnosed SARS-CoV-2 infections during first wave

GenScript and Duke-NUS announce notice of allowance for “Surrogate Virus Neutralization Technology”

GenScript and Duke-NUS announce notice of allowance for “Surrogate Virus Neutralization Technology”

Ycharos announces publication of first characterization data and formation of industry advisory committee

Ycharos announces publication of first characterization data and formation of industry advisory committee

Combination of SFRP2 and PD-1 immunotherapy halts aggressive metastatic cancer in preclinical model

Combination of SFRP2 and PD-1 immunotherapy halts aggressive metastatic cancer in preclinical model

New antibody-drug conjugates also kill non-targeted neighboring tumor cells

New antibody-drug conjugates also kill non-targeted neighboring tumor cells

New universal vaccine protects mice against COVID-19 and other coronaviruses

New universal vaccine protects mice against COVID-19 and other coronaviruses

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.